Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
November 30, 2012
Primary Completion Date
February 28, 2017
Study Completion Date
May 31, 2026
Conditions
Untreated Stage III Melanoma or Stage IV Melanoma
Interventions
BIOLOGICAL
Ipilimumab
3 mg/kg
DRUG
Carboplatin
AUC = 6
DRUG
Paclitaxel
175 mg/m2
Trial Locations (1)
H3T 1E2
Jewish General Hospital, Montreal
All Listed Sponsors
lead
Jewish General Hospital
OTHER
NCT01676649 - Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | Biotech Hunter | Biotech Hunter